vs

Side-by-side financial comparison of INSEEGO CORP. (INSG) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $48.4M, roughly 1.6× INSEEGO CORP.). On growth, INSEEGO CORP. posted the faster year-over-year revenue change (0.6% vs -36.9%). INSEEGO CORP. produced more free cash flow last quarter ($11.6M vs $-6.6M). Over the past eight quarters, INSEEGO CORP.'s revenue compounded faster (13.6% CAGR vs -34.4%).

Inseego Corp designs, manufactures and delivers advanced 5G and IoT solutions including mobile hotspots, edge computing devices, and cloud-based device management platforms. It primarily serves telecom operators, enterprise clients, and public sector customers across global markets.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

INSG vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.6× larger
MED
$75.1M
$48.4M
INSG
Growing faster (revenue YoY)
INSG
INSG
+37.5% gap
INSG
0.6%
-36.9%
MED
More free cash flow
INSG
INSG
$18.2M more FCF
INSG
$11.6M
$-6.6M
MED
Faster 2-yr revenue CAGR
INSG
INSG
Annualised
INSG
13.6%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INSG
INSG
MED
MED
Revenue
$48.4M
$75.1M
Net Profit
$469.0K
Gross Margin
42.2%
69.4%
Operating Margin
2.7%
-10.4%
Net Margin
1.0%
Revenue YoY
0.6%
-36.9%
Net Profit YoY
182.9%
EPS (diluted)
$-0.02
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INSG
INSG
MED
MED
Q4 25
$48.4M
$75.1M
Q3 25
$45.9M
$89.4M
Q2 25
$40.2M
$105.6M
Q1 25
$31.7M
$115.7M
Q4 24
$48.1M
$119.0M
Q3 24
$54.0M
$140.2M
Q2 24
$51.6M
$168.6M
Q1 24
$37.5M
$174.7M
Net Profit
INSG
INSG
MED
MED
Q4 25
$469.0K
Q3 25
$1.4M
$-2.3M
Q2 25
$507.0K
$2.5M
Q1 25
$-1.6M
$-772.0K
Q4 24
$-566.0K
Q3 24
$9.0M
$1.1M
Q2 24
$624.0K
$-8.2M
Q1 24
$-4.5M
$8.3M
Gross Margin
INSG
INSG
MED
MED
Q4 25
42.2%
69.4%
Q3 25
41.6%
69.5%
Q2 25
41.1%
72.6%
Q1 25
47.3%
72.8%
Q4 24
37.3%
74.1%
Q3 24
34.8%
75.4%
Q2 24
36.4%
73.2%
Q1 24
35.3%
72.8%
Operating Margin
INSG
INSG
MED
MED
Q4 25
2.7%
-10.4%
Q3 25
4.7%
-4.6%
Q2 25
3.2%
-1.0%
Q1 25
-1.3%
-1.1%
Q4 24
3.7%
0.6%
Q3 24
1.9%
1.5%
Q2 24
3.6%
-4.7%
Q1 24
-7.9%
4.5%
Net Margin
INSG
INSG
MED
MED
Q4 25
1.0%
Q3 25
3.1%
-2.5%
Q2 25
1.3%
2.3%
Q1 25
-5.0%
-0.7%
Q4 24
-1.2%
Q3 24
16.6%
0.8%
Q2 24
1.2%
-4.8%
Q1 24
-11.9%
4.8%
EPS (diluted)
INSG
INSG
MED
MED
Q4 25
$-0.02
$-1.64
Q3 25
$0.03
$-0.21
Q2 25
$-0.03
$0.22
Q1 25
$-0.16
$-0.07
Q4 24
$0.62
$0.08
Q3 24
$-0.06
$0.10
Q2 24
$-0.02
$-0.75
Q1 24
$-0.44
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INSG
INSG
MED
MED
Cash + ST InvestmentsLiquidity on hand
$24.9M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-4.0M
$198.9M
Total Assets
$93.8M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INSG
INSG
MED
MED
Q4 25
$24.9M
$167.3M
Q3 25
$14.6M
$173.5M
Q2 25
$13.2M
$162.7M
Q1 25
$35.1M
$164.6M
Q4 24
$39.6M
$162.3M
Q3 24
$12.0M
$170.0M
Q2 24
$49.0M
$163.5M
Q1 24
$12.3M
$156.4M
Stockholders' Equity
INSG
INSG
MED
MED
Q4 25
$-4.0M
$198.9M
Q3 25
$-7.7M
$214.7M
Q2 25
$-10.5M
$216.0M
Q1 25
$-13.0M
$211.0M
Q4 24
$-12.9M
$210.1M
Q3 24
$-85.1M
$207.3M
Q2 24
$-101.8M
$205.3M
Q1 24
$-105.6M
$211.0M
Total Assets
INSG
INSG
MED
MED
Q4 25
$93.8M
$248.0M
Q3 25
$85.8M
$268.2M
Q2 25
$83.1M
$269.3M
Q1 25
$93.0M
$280.0M
Q4 24
$100.0M
$284.2M
Q3 24
$113.4M
$291.2M
Q2 24
$149.6M
$293.5M
Q1 24
$122.1M
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INSG
INSG
MED
MED
Operating Cash FlowLast quarter
$12.0M
$-5.3M
Free Cash FlowOCF − Capex
$11.6M
$-6.6M
FCF MarginFCF / Revenue
24.0%
-8.8%
Capex IntensityCapex / Revenue
0.7%
1.8%
Cash ConversionOCF / Net Profit
25.50×
TTM Free Cash FlowTrailing 4 quarters
$6.5M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INSG
INSG
MED
MED
Q4 25
$12.0M
$-5.3M
Q3 25
$3.2M
$12.1M
Q2 25
$-4.5M
$-3.4M
Q1 25
$-3.5M
$3.4M
Q4 24
$-14.2M
$-4.9M
Q3 24
$14.8M
$9.1M
Q2 24
$27.6M
$13.1M
Q1 24
$5.2M
$7.3M
Free Cash Flow
INSG
INSG
MED
MED
Q4 25
$11.6M
$-6.6M
Q3 25
$3.1M
$10.8M
Q2 25
$-4.7M
$-4.8M
Q1 25
$-3.5M
$1.9M
Q4 24
$-14.3M
$-7.2M
Q3 24
$14.8M
$7.7M
Q2 24
$27.6M
$11.1M
Q1 24
$5.4M
FCF Margin
INSG
INSG
MED
MED
Q4 25
24.0%
-8.8%
Q3 25
6.7%
12.0%
Q2 25
-11.6%
-4.5%
Q1 25
-11.0%
1.6%
Q4 24
-29.7%
-6.1%
Q3 24
27.4%
5.5%
Q2 24
53.5%
6.6%
Q1 24
3.1%
Capex Intensity
INSG
INSG
MED
MED
Q4 25
0.7%
1.8%
Q3 25
0.2%
1.5%
Q2 25
0.5%
1.3%
Q1 25
0.1%
1.3%
Q4 24
0.1%
1.9%
Q3 24
0.0%
1.0%
Q2 24
0.0%
1.1%
Q1 24
0.0%
1.1%
Cash Conversion
INSG
INSG
MED
MED
Q4 25
25.50×
Q3 25
2.22×
Q2 25
-8.81×
-1.36×
Q1 25
Q4 24
Q3 24
1.65×
8.04×
Q2 24
44.31×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons